Immuron Limited · ASX:IMC
Immuron — 21st Virtual Investor Summit Microcap Event (November 2024)
19 slides from Immuron's conference presentation, Nov 22, 2024

Slide 1: Immuron CEO presentation to 21st Virtual Investor Summit Microcap Event
a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event Melbourne, Australia, November 22, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our C

Slide 2: © Immuren
© Immuren

Slide 3: Immuron Platform Technology
Immuron Platform Technology Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine

Slide 4: © Immuren
© Immuren

Slide 5: References
References Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012. Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium diff

Slide 6: © Immuren
© Immuren

Slide 7: Virtual Investor Summit Microcap Event, November 2024
21 November 2024 Steven Lydeamore Chief Executive Officer Virtual Investor Summit Microcap Event NASDAQ: IMRN ASX: IMC

Slide 8: Forward-looking statements
Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to i

Slide 9: Executive summary
3 Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Two commercially available oral immunotherapeutic products – Travelan® and Protect

Slide 10: Opportunity to Convert Billion Dollar Traveller's Diarrhoea Market from Relief to Prevention
4 Opportunity to Convert Billion Dollar Traveller’s Diarrhoea Market from Relief to Prevention by Travelan® Billion Dollar Market Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7% 1 Industry tailwinds International travel continues to grow Travel to high - risk destination

Slide 11: Travelan continued strong sales growth
5 Travelan® continued strong sales growth Global + Q1 FY2025 AUD$1.5 million up 13% on prior quarter Australia + Q1 2025 AUD$1.0 million up 3% on prior quarter + Secured core ranging in another nine pharmacy banner groups North America + Q1 2025 AUD$0.5 million up 48% on prior quarter + Strongest mo

Slide 12: Continued strong sales growth
6 6 CONTINUED STRONG SALES GROWTH o Global sales increased by 172% in the 2024 fiscal year to a record A$4.90 million compared to A$1.80 million in FY23 o Record monthly sales in October 2024 of $1.49 million o Australia o FY24: a record A$3.75 million; up 223% o Q1, FY25: A$1.01 million o October 2

Slide 13: Expansion of Travelan distribution
7 7 EXPANSION OF TRAVELAN® DISTRIBUTION

Slide 14: Consumer marketing activity driving Travelan sales growth
8 8 CONSUMER MARKETING ACTIVITY DRIVING TRAVELAN® SALES GROWTH We continue to drive awareness, consideration and engagement o Ranging across major retailers (Australia, Canada) o In - store positioning and promotion o Retailer catalogues o Search and social media marketing o Social competitions o Us

Slide 15: World first triple mechanism of action for CDI IMM-529
WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI IMM - 529: pre - IND filed with FDA July 2024; successful pre - IND meeting IMM - 529 will be indicated for the treatment of recurrent C. difficile infection Indication / Target Population • Novel antibody - containing therapeutic which neutralizes C. d

Slide 16: Immuron's clinical programs – opportunity assessment
10 10 IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT Corporate › Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need › Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demon

Slide 17: Upcoming Milestones
11 Upcoming Milestones Revenue + Continued quarter on quarter growth from growth drivers + Secured core ranging in another nine Australian pharmacy banner groups + Strongest monthly sales on amazon.com in September 2024 + Secured distribution in ten pharmacy/grocery retailers in Canada + Record mont

Slide 18: Contact information
EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION:

Slide 19: Scientific references
13 Scientific references Travelan® (IMM - 124E) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Military Health System Research Sy
Source: SEC EDGAR · 6-K filed Nov 22, 2024
More decks from Immuron Limited
Shareholder Meeting (November 2026)8 slides · Nov 18, 2026
Shareholder Meeting (November 2026)11 slides · Nov 18, 2026
Emerging Growth Conference (October 2026)13 slides · Oct 28, 2026
Emerging Growth Conference 202616 slides · Oct 28, 2026
Coffee Microcaps Conference 202615 slides · Sep 22, 2026
Coffee Microcaps Conference (September 2026)12 slides · Sep 22, 2026